导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.17% | 2860/4773 |
| 近一周 | -2.18% | 1411/5462 |
| 近一月 | -4.15% | 2255/5421 |
| 近一季 | -7.44% | 2404/5209 |
| 近半年 | -2.96% | 2077/4920 |
| 近一年 | 0.16% | 2629/4366 |
| 近两年 | 43.62% | 1703/2954 |
| 近三年 | 25.40% | 1262/2253 |
| 成立以来 | 48.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.69% 3352/4961 |
11.86% 2280/5312 |
- - |
- - |
| 2025 | 19.12% 2248/4813 |
-1.07% 2569/3635 |
2.13% 1828/4076 |
17.81% 2432/4524 |
0.07% 2242/4813 |
| 2024 | 15.90% 866/3463 |
2.67% 732/2808 |
-1.29% 1026/3014 |
16.50% 1435/3129 |
-1.83% 1852/3463 |
| 2023 | -9.54% 1187/2656 |
4.12% 1046/2280 |
-4.00% 1003/2385 |
-3.04% 832/2515 |
-6.67% 1867/2655 |
| 2022 | -19.77% 893/2207 |
-13.99% 889/1919 |
6.57% 661/2016 |
-13.80% 975/2113 |
1.55% 1227/2208 |
| 2021 | -3.93% 934/1822 |
-3.29% 794/1255 |
4.06% 928/1330 |
-5.83% 866/1466 |
1.37% 954/1822 |
| 2020 | 25.97% 611/1250 |
-9.82% 721/1028 |
12.99% 656/1067 |
10.06% 591/1164 |
12.33% 479/1184 |
| 2019 | 35.35% 378/1092 |
26.50% 401/754 |
-0.31% 250/804 |
0.55% 509/850 |
6.74% 557/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.86% 368/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实沪深300ETF联接C VS. 长安沪深300非周期A(740101) |